BRCA1 and neoplasm: Together with the low sensitivity to niraparib, this suggests that suppressor mutations may have arisen in the tumour or the cell line, but an analysis of the coding mutations did not reveal any alterations in known HR-interacting genes to explain the limited BRCA1-like phenotype of SUM149PT.